Estimados colegas:
Tal y como hemos realizado con congresos previos, a lo largo de la celebración del Congreso Europeo de Cardiología (Amsterdam, 31 de Agosto al 4 de Septiembre) comentaremos en el blog los principales resultados de los ensayos clínicos más importantes.
Hot Line I: Late Breaking Trials on Thrombosis (September 1)
Chairpersons: Panagiotis VARDAS (Heraklion, GR), Keith FOX (Edinburgh, GB)
Treatment of venous thromboembolism, the Hokusai VTE study–Harry BULLER (Amsterdam, NL)
TASTE: Thrombus aspiration during ST-segment elevation myocardial infarction. A multicenter, prospective, registry based randomized clinical trial– Ole FROBERT (Orebro, SE)
TAO: Otamixaban in non-ST-segment elevation acute coronary syndrome patients undergoing a planned invasive strategy– Philippe Gabriel STEG (Paris Cedex, FR)
RE-ALIGN: Dabigatran in patients with a mechanical heart valve– Frans VAN DE WERF (Leuven, BE)
PARIS: Incidence and Impact of Dual Antiplatelet Therapy Cessation On Adverse Cardiac Events Following Percutaneous Coronary Intervention: Two-Year Results from the Patterns of Non-Adherence to Anti-Platelet Regimens In Stented Patients (PARIS) Study– Roxana MEHRAN (New York, US)
Hot Line II: Late Breaking Trials on Intervention and devices (September 1)
Chairpersons: Mariell JESSUP (Philadelphia, US), Fausto Jose PINTO (Lisbon, PT)
PRAMI: Preventive Angioplasty in Myocardial Infarction Trial– David WALD (London, GB)
ACCOAST: A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention or as Pre-treatment At the Time of Diagnosis in Patients with Non-ST-Elevation Myocardial Infarction- Gilles MONTALESCOT (Paris, FR)
DECAAF: Delayed Enhancement – MRI determinant of successful Catheter Ablation of Atrial Fibrillation (DECAAF): Analysis of post ablation scar and outcome– Nassir MARROUCHE (Salt Lake City, US)
PRAGUE 14: Perioperative ischemia versus perioperative bleeding in consecutive cardiac patients undergoing non-cardiac surgery– Petr WIDIMSKY (Prague, CZ)
LINC study: LINC – A multicenter randomized trial comparing a mechanical CPR algorithm using LUCAS vs. manual CPR in out-of-hospital cardiac arrest patients– Sten RUBERTSSON (Uppsala, SE)
IN-TIME Study – The Influence of Implant-Based Home Monitoring on the Clinical Management of Heart Failure Patients with an Impaired Left Ventricular Function-Gerhard HINDRICKS (Leipzig, DE)
Hot Line III: Late Breaking Trials on Risk factors and Diabetes (September 2)
Chairpersons: Jeroen BAX (Leiden, NL), John Gordon HAROLD (Los Angeles, US)
PURE: Contrasting associations between risk factor burden, CVD incidence and mortality in high, middle and low income countries– Salim YUSUF (Hamilton, CA)
EXAMINE: EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome– William B WHITE (Farmington, US)
SAVOR-TIMI 53: Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 Study– Deepak BHATT (Newton, US)
ASSURE: Effect of an Oral Agent Inducing Apo A-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study– Stephen James NICHOLLS (Adelaide, AU)
COMPARE: Effect of losartan on aortic dilatation rate in adults with Marfan Syndrome– Barbara Jm MULDER (Amsterdam, NL)
Hot Line IV: Late Breaking Trials on Heart Failure and Acute Coronary Syndrome (September 3)
Chairpersons: Donna ARNETT (Birmingham, US), Michel KOMAJDA (Paris, FR)
Centenary of the Tour de France Group: Mortality of French Participants from the Tour de France 1947-2012– Xavier JOUVEN (Paris, FR)
ATOMIC-AHF: Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: Results from ATOMIC-AHF– John R TEERLINK (San Francisco, US)